Esteve Healthcare SL (Esteve) is a specialty pharmaceutical company that is involved in the research, development, manufacture, and commercialization of novel pharmaceuticals, OTC and chemicals addressing various clinical indications. The company offers an array of products in analgesia, central nervous system (CNS), respiratory, pain, oncology and ophthalmology. The company focuses on delivering innovative treatments in key therapeutic areas such as neuroscience, ophthalmology, and chronic pathologies including diabetes and hypercholesterolemia. The company offers an array of R&D services, including API manufacturing and advanced intermediate technologies. These experts combine experience with a dedication to innovation, utilizing techniques such as flow chemistry, biocatalysis, and process engineering to develop safer and more efficient manufacturing processes. The company offers products for treatments across various therapeutic areas. In neurology, the company focuses on developing therapies to address conditions such as Alzheimer's disease, Parkinson's disease, and epilepsy. In ophthalmology, the company is dedicated to researching and developing treatments for eye diseases such as dry eye and glaucoma. Esteve offers treatments for chronic pathologies like diabetes and hypercholesterolemia. Leveraging its expertise in API manufacturing and advanced intermediate technologies.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Esteve’s research and development (R&D) activities focus on the development of novel therapeutic solutions targeting unmet medical needs. It works in areas such as in silico drug design, cellular and molecular biology, medical chemistry, pharmacology, pre-clinical development, clinical development, pharmaceutical development, quality assurance, regulatory affairs, industrial property, pharmacological safety, and pharmacovigilance. Its program E-58425 has been submitted for market approval for the treatment of neuropathic pain and severe and chronic pain (moderate to intense). It has other products such as EGT-101 for gene therapy; E-64401, E-64514, E-64454 for the Sigma-1 platform; and E-85819, E-86657 for Multimodal NMEs, which are in the preclinical development stage. Its R&D department, spanning across three continents, is equipped with state-of-the-art facilities and staffed by over 100 individuals. The company’s R&D portfolio includes new chemical entities in fields like neurology and analgesia and advanced therapies for inherited metabolic disorders. The company is implementing various programs that are in different stages of research and development. The company is focusing on proprietary specialty therapies to deliver new solutions for patients who lack effective options. In FY2025, the company spent EUR 49 million on R&D expenses, which accounted for 5.9% of the company’s revenue.